Neurocrine Biosciences, Inc. technical analysis
Technical analysis of Neurocrine Biosciences, Inc. (stock) with the Montbon Method — Elliott Waves, moving averages and a 0–100 score.
What is Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders. The company markets several approved products including INGREZZA for tardive dyskinesia, Orilissa for endometriosis, and Oriahnn for uterine fibroids, along with drug candidates in clinical development for conditions such as depression, schizophrenia, Alzheimer's disease, and epilepsy. Founded in 1992, Neurocrine Biosciences is headquartered in San Diego, California, and maintains collaboration agreements with international pharmaceutical partners.
Description generated automatically from public sources; it may be inaccurate or out of date.
Neurocrine Biosciences, Inc.: latest session data
Closing values for October 16, 2026, computed on the last 12 months of prices.
Moving averages
21 sessions
140.78 $
−3.21%
50 sessions
149.27 $
−8.72%
200 sessions
147.05 $
−7.34%
Session levels
s2
134.23
Support
s1
135.59
Support
pivot
136.91
Pivot
r1
138.27
Resistance
r2
139.59
Resistance
How to read it
In the October 16, 2026 session Neurocrine Biosciences, Inc. closed lower at 136.25 $, −0.51% versus the previous session.
The price sits below every moving average observed: −3.21% against the 21-session average, −8.72% against the 50 and −7.34% against the 200.
The 14-period RSI reads 35.2, in neutral territory.
MACD stands at -3.704 against a signal line at -3.624: the histogram is negative (−0.079).
ADX reads 28.2, indicating a marked directionality.
Levels computed on the latest session place supports at 135.59 and 134.23 $ and resistances at 138.27 and 139.59 $, around a pivot of 136.91.
The average daily range (ATR) is 3.843 $, or 2.82% of price.
Turnover was 312.8K shares, 23% of the 20-session average.
Over the last twelve months the price ranged between 126.48 and 186.12 $, and today stands −26.79% from the period high.
Measures computed on closing prices. They describe the past; they are not forecasts.
Score, Elliott Waves, moving averages and technical indicators — free, no card
If you're not registered we'll ask you to sign in (free), then open the NBIX analysis.
How Montbon’s technical analysis works
Montbon analyses markets with Elliott Waves, multi-timeframe moving averages and a 0–100 score summarising the technical setup. It is an informational screening tool.
Elliott Waves
Wave counting to frame the price structure.
MTF moving averages
Moving averages across timeframes to read the trend.
0–100 score
A technical summary of the setup, updated daily.
FAQ about Neurocrine Biosciences, Inc.
How is Neurocrine Biosciences, Inc. analysed technically?
Technical analysis of Neurocrine Biosciences, Inc. is based on price charts and indicators such as moving averages, RSI and MACD, to observe trend, momentum and volatility across different time horizons.
Which timeframes are used for Neurocrine Biosciences, Inc.?
The daily and weekly charts are typically used for medium-to-long-term trends, while intraday charts (for example 1-hour or 15-minute) are used for short-term movements.
What are Elliott Waves applied to Neurocrine Biosciences, Inc.?
Elliott Wave theory describes price moves as sequences of impulsive and corrective waves; applied to Neurocrine Biosciences, Inc. it helps frame the technical structure of the historical chart and is not a forecast.
Other tickers to analyse
Disclaimer. For informational purposes only; not financial advice or a recommendation. Montbon Analytics is not an authorised financial intermediary.
Are you an issuer and want a correction or removal? Write to info@montbon.com.